|
[1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatits B:a 2015 update[J].J Clin Hapetol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
|
[2]MANZOOR S,SAALIM M,IMRAN M,et al.Hepatitis B virus therapy:what’s the future holding for us:the future[J].World JGastroenterol,2015,21(44):12558-12575.
|
|
[3] Hepatits B foundation drug watch.Compounds in development for chronic hepatitis B[EB/OL].(2016-03-25)http://www.hepb.org/professionals/hbf_drug_watch.htm.
|
|
[4]PREZ-CAMEO C,PONS M,ESTEBAN R.New therapeutic perspectives in HBV:when to stop NAs[J].Liver Int,2014,34(1):146-153.
|
|
[5]YANG FQ,RAO GR.Research progress of therapeutic vaccines against hepatitis B[J].Infect Dis Info,2015,28(2):65-69.(in Chinese)杨富强,饶桂荣.乙型肝炎治疗性疫苗研究进展[J].传染病信息,2015,28(2):65-69.
|
|
[6] XUE M,FAN F,DING L,et al.An autophagosome-based therapeutic vaccine for HBV infection:a preclinical evaluation[J].JTransl Med,2014,12:361.
|
|
[7]WANG JZ,YANG DL.Immune modulation treatment of chronic hepatits B virus infection[J].Chin J Hepatol,2015,23(3):227-230.(in Chinese)王俊忠,杨东亮.免疫调节治疗慢性乙型肝炎病毒感染的研究进展[J].中华肝脏病杂志,2015,23(3):227-230.
|
|
[8]MARTIN P,DUBOIS C,JACQUIER E,et al.TG1050,an immunotherapeutic to treat chronic hepatitis B,induces robust T cells and exerts an antiviral effect in HBV-persistent mice[J].Gut,2015,64(12):1961-1971.
|
|
[9]GANE EJ,LIM YS,GORDON SC,et al.The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection[J].J Hepatol,2015,63(2):320-328.
|
|
[10]LANFORD RE,GUERRA B,CHAVEZ D,et al.GS-9620,an oral agonist of Toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees[J].Gastroenterology,2013,144(7):1508-1517.
|
|
[11]BILLIOUD G,PICHOUD C,PUERSTINGER G,et al.The main hepatitis B virus(HBV)mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication[J].Antiviral Res,2011,92(2):271-276.
|
|
[12]WU G,LIU B,ZHANG Y,et al.Preclinical characterization of GLS4,an inhibitor of hepatitis B virus core particle assembly.[J].Antimicrob Agents Chemother,2013,57(11):5344-5354.
|
|
[13]WU Y,HAN L,YUAN YF.Meta-analysis of telbivudine and lamivudine in the treatment of chronic hepatitis B[J].China Med Herald,2014,11(28):11-13,18.(in Chinese)吴岩,韩璐,原永芳.替比夫定和拉米夫定治疗慢性乙型肝炎的Meta分析[J].中国医药导报,2014,11(28):11-13,18.
|
|
[14]WANG J.Efficacy of lamivudine combined with adefovir dipivoxil in treatment of chronic hepatitis B cirrhosis[J].J Clin Exp Med,2014,13(6):498-500.(in Chinese)王婧.拉米夫定联合阿德福韦酯治疗慢性乙型肝炎肝硬化的疗效观察[J].临床和实验医学杂志,2014,13(6):498-500.
|
|
[15] YANG HC,KAO JH.HBV cure-can we pin our hopes on immunotherapy?[J].Nat Rev Gastroenterol Hepatol,2015,12(3):129-131.
|
|
[16]LIN CL,YANG HC,KAO JH.Hepatitis B virus:new therapeutic perspectives[J].Liver Int,2016,36(1):85-92.
|
DownLoad: